Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Verona Pharma stock | $7.9

Own Verona Pharma stock in just a few minutes.

Fact checked

Verona Pharma plc is a biotechnology business based in the US. Verona Pharma shares (VRNA) are listed on the NASDAQ and all prices are listed in US Dollars. Verona Pharma employs 33 staff and has a market cap (total outstanding shares value) of USD$322 million.

How to buy shares in Verona Pharma

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Verona Pharma. Find the stock by name or ticker symbol: VRNA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Verona Pharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$7.9, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Verona Pharma, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Verona Pharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Verona Pharma share price

Use our graph to track the performance of VRNA stocks over time.

Verona Pharma shares at a glance

Information last updated 2020-12-01.
Latest market closeUSD$7.9
52-week rangeUSD$2.01 - USD$9.5
50-day moving average USD$6.338
200-day moving average USD$6.2506
Wall St. target priceUSD$18.8
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.336

Buy Verona Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Verona Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Verona Pharma price performance over time

Historical closes compared with the close of $7.9 from 2020-12-09

1 week (2021-01-06) N/A
1 month (2020-12-13) N/A
3 months (2020-10-13) N/A
6 months (2020-07-13) N/A
1 year (2020-01-13) N/A
2 years (2019-01-13) N/A
3 years (2018-01-13) N/A
5 years (2016-01-13) N/A

Verona Pharma financials

Gross profit TTM USD$0
Return on assets TTM -22.5%
Return on equity TTM -41.82%
Profit margin 0%
Book value $4.587
Market capitalisation USD$322 million

TTM: trailing 12 months

Shorting Verona Pharma shares

There are currently 56,946 Verona Pharma shares held short by investors – that's known as Verona Pharma's "short interest". This figure is 27.5% down from 78,577 last month.

There are a few different ways that this level of interest in shorting Verona Pharma shares can be evaluated.

Verona Pharma's "short interest ratio" (SIR)

Verona Pharma's "short interest ratio" (SIR) is the quantity of Verona Pharma shares currently shorted divided by the average quantity of Verona Pharma shares traded daily (recently around 103538.18181818). Verona Pharma's SIR currently stands at 0.55. In other words for every 100,000 Verona Pharma shares traded daily on the market, roughly 550 shares are currently held short.

However Verona Pharma's short interest can also be evaluated against the total number of Verona Pharma shares, or, against the total number of tradable Verona Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Verona Pharma's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Verona Pharma shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Verona Pharma shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Verona Pharma.

Find out more about how you can short Verona Pharma stock.

Verona Pharma share dividends

We're not expecting Verona Pharma to pay a dividend over the next 12 months.

Verona Pharma share price volatility

Over the last 12 months, Verona Pharma's shares have ranged in value from as little as $2.01 up to $9.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Verona Pharma's is 0.418. This would suggest that Verona Pharma's shares are less volatile than average (for this exchange).

Verona Pharma overview

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on develops and commercializes therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine (RPL554), is an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The formulations of ensifentrine are under development for the treatment chronic obstructive pulmonary disease (COPD): nebulized ensifentrine is in Phase 2b clinical development for the maintenance treatment of COPD; and a dry powder inhaler and a pressurized metered-dose inhaler. The company also focuses on developing ensifentrine for the treatment of cystic fibrosis and asthma. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site